Browse by People

Collapse authors list.
Mosenzon, Ofri, Raz, Itamar, Wiviott, Stephen D, Schechter, Meir, Goodrich, Erica L, Yanuv, Ilan, Rozenberg, Aliza, Murphy, Sabina A, Zelniker, Thomas A, Langkilde, Anna Maria et al (show 11 more authors) , Gause-Nilsson, Ingrid AM, Fredriksson, Martin, Johansson, Peter A, Wilding, John PH ORCID: 0000-0003-2839-8404, McGuire, Darren K, Bhatt, Deepak L, Leiter, Lawrence A, Cahn, Avivit, Dwyer, Jamie P, Heerspink, Hiddo JL and Sabatine, Marc S (2022) Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial. DIABETES CARE, 45 (10). pp. 2350-2359.

Collapse authors list.
Mosenzon, Ofri, Wiviott, Stephen D, Cahn, Avivit, Rozenberg, Aliza, Yanuv, Ilan, Goodrich, Erica L, Murphy, Sabina A, Heerspink, Hiddo JL, Zelniker, Thomas A, Dwyer, Jamie P et al (show 11 more authors) , Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Wilding, John PH ORCID: 0000-0003-2839-8404, Kato, Eri T, Gause-Nilson, Ingrid AM, Fredriksson, Martin, Johansson, Peter A, Langkilde, Anna Maria, Sabatine, Marc S and Raz, Itamar (2019) Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. LANCET DIABETES & ENDOCRINOLOGY, 7 (8). pp. 606-617.

Brown, Emily, Heerspink, Hiddo JL, Cuthbertson, Daniel J ORCID: 0000-0002-6128-0822 and Wilding, John PH ORCID: 0000-0003-2839-8404 (2021) SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. LANCET, 398 (10296). pp. 262-276.